Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Stefan Bielack
Teleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group (COSS)
1 Introduction Teleangiectatic osteosarcoma represents one of the fully malignant subtypes of conventional osteosarcoma currently recognized by the World Health Organization (WHO) [1]. Histopathologically, it is characterized by cystic spaces which may be empty or blood-filled. These are lined by highly atypical neoplastic cells often exhibiting atypical mitoses. While rather scarce in some tumors, osteoid formation by the neoplastic cells is a sine qua non for making this diagnosis [1, 2].
Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)
COSS Cooperative Osteosarcoma Study Group CWS Cooperative Weichteilsarkom Studienguppe RMS rhabdomyosarcoma STEAP-9 six-transmembrane epithelial antigen of the prostate-9 1 INTRODUCTION Secondary osteosarcomas may arise in patients who previously suffered from other sarcomas, particularly rhabdomyosarcoma (RMS).
Cancers | Free Full-Text | Osteosarcoma Arising as a Secondary Malignancy following Treatment for Hematologic Cancer: A Report of 33 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS)
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS)
Abstract : Simple Summary The Cooperative Osteosarcoma Study Group (COSS), active since the late 1970s, is a multi-institutional consortium representing Germany, Austria, and Switzerland. Its goals are to cure as many osteosarcoma patients as possible with as few late effects as achievable. Over the decades, COSS has amassed and followed more than 5000 affected patients into trials and its registry. This has allowed the group to perform many meaningful analyses.
Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults
Original Article Stefanie J. Kube MD, Corresponding Author Stefanie J. Kube MD s.kube@klinikum-stuttgart.de orcid.org/0000-0002-7757-792X Pediatrics 1, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany Corresponding Author: Stefanie J. Kube, MD, Pediatrics 1, Klinikum Stuttgart-Olgahospital, Kriegsbergstr. 62, D-70174 Stuttgart, Germany (s.kube@klinikum-stuttgart.de).
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study
Highlights • This is the first prospective study conducted on patients with dedifferentiated chondrosarcoma. • Addition of chemotherapy to surgery was feasible. • Chemotherapy gave favourable survival compared with previous retrospective studies. • Almost half of the patients in complete surgical remission were alive. Abstract Introduction The role of chemotherapy for patients with dedifferentiated chondrosarcoma (DDCS) is still under discussion.
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
1. Introduction Osteosarcoma is a malignant bone tumour mainly affecting children and young adults. Although osteosarcoma is the most common primary malignant bone cancer, it is a rare disease and has an annual incidence of 3–4 patients per million. The introduction of multi-agent chemotherapy several decades ago improved 5-year event-free survival in localised high-grade osteosarcoma from less than 20% to around 60%.
Novel insights and therapeutic interventions for pediatric osteosarcoma
High-grade osteosarcomas are the most common primary malignant tumors of bone. With complete surgical resection and multi-agent chemotherapy up to 70% of patients with high-grade osteosarcomas and localized extremity tumors can become long-term survivors. The prognosis, however, is poor for patients with nonresectable, primary metastatic or relapsed disease. Outcome is essentially unchanged for three decades.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Stefan
Contact Stefan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack